Wellington Shields Capital Management LLC decreased its position in Stryker Co. (NYSE:SYK) by 37.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,150 shares of the medical technology company’s stock after selling 700 shares during the period. Wellington Shields Capital Management LLC’s holdings in Stryker were worth $249,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in Stryker by 2.1% in the 2nd quarter. Vanguard Group Inc. now owns 26,735,288 shares of the medical technology company’s stock worth $5,496,241,000 after acquiring an additional 555,327 shares during the last quarter. Northern Trust Corp raised its stake in Stryker by 0.5% in the 2nd quarter. Northern Trust Corp now owns 3,922,830 shares of the medical technology company’s stock worth $806,455,000 after acquiring an additional 19,248 shares during the last quarter. Nuveen Asset Management LLC raised its stake in Stryker by 20,218.6% in the 2nd quarter. Nuveen Asset Management LLC now owns 2,596,110 shares of the medical technology company’s stock worth $533,708,000 after acquiring an additional 2,583,333 shares during the last quarter. Morgan Stanley raised its stake in Stryker by 3.4% in the 2nd quarter. Morgan Stanley now owns 1,826,762 shares of the medical technology company’s stock worth $375,547,000 after acquiring an additional 59,305 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in Stryker by 3.4% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 1,357,591 shares of the medical technology company’s stock worth $279,094,000 after acquiring an additional 44,907 shares during the last quarter. Institutional investors own 73.13% of the company’s stock.

In other news, CFO Glenn S. Boehnlein sold 2,700 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $215.85, for a total transaction of $582,795.00. Following the sale, the chief financial officer now directly owns 17,933 shares in the company, valued at approximately $3,870,838.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kevin Lobo sold 19,286 shares of the firm’s stock in a transaction dated Thursday, October 31st. The shares were sold at an average price of $215.71, for a total value of $4,160,183.06. The disclosure for this sale can be found here. Insiders have sold a total of 67,524 shares of company stock worth $14,731,927 over the last 90 days. Insiders own 7.20% of the company’s stock.

Shares of NYSE:SYK traded up $1.76 during trading on Tuesday, reaching $200.18. 1,277,792 shares of the company’s stock traded hands, compared to its average volume of 1,231,268. Stryker Co. has a fifty-two week low of $144.75 and a fifty-two week high of $223.45. The company has a quick ratio of 1.35, a current ratio of 2.18 and a debt-to-equity ratio of 0.64. The firm has a market cap of $74.74 billion, a PE ratio of 27.38, a P/E/G ratio of 2.45 and a beta of 0.80. The company has a 50-day simple moving average of $211.87 and a 200-day simple moving average of $205.88.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, October 29th. The medical technology company reported $1.91 EPS for the quarter, beating the Zacks’ consensus estimate of $1.90 by $0.01. Stryker had a return on equity of 25.33% and a net margin of 23.55%. The firm had revenue of $3.59 billion for the quarter, compared to analysts’ expectations of $3.58 billion. During the same period last year, the firm earned $1.69 EPS. The company’s quarterly revenue was up 10.6% on a year-over-year basis. On average, equities research analysts forecast that Stryker Co. will post 8.23 EPS for the current year.

Several brokerages have weighed in on SYK. BMO Capital Markets set a $216.00 price target on Stryker and gave the stock a “hold” rating in a research report on Friday, July 26th. BTIG Research set a $228.00 price target on Stryker and gave the stock a “buy” rating in a research report on Thursday, September 5th. Robert W. Baird increased their price target on Stryker from $239.00 to $242.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Morgan Stanley increased their price target on Stryker from $218.00 to $230.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 16th. Finally, Stifel Nicolaus increased their price target on Stryker from $230.00 to $245.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Six investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $220.17.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Featured Article: Market Capitalization

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.